RARE - Ultragenyx Pharmaceutical Inc.

NasdaqGS - NasdaqGS Delayed price. Currency in USD
47.86
+0.21 (+0.44%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous close47.65
Open47.89
Bid40.00 x 100
Ask59.95 x 100
Day's range46.57 - 48.36
52-week range41.67 - 91.35
Volume534,537
Avg. volume595,474
Market cap2.374B
Beta2.16
PE ratio (TTM)N/A
EPS (TTM)-6.97
Earnings date2 May 2018 - 7 May 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est64.71
Trade prices are not sourced from all markets
  • PR Newswireyesterday

    Kyowa Kirin and Ultragenyx Announce Crysvita® (burosumab) Receives Conditional Marketing Authorisation in Europe for the Treatment of X-Linked Hypophosphatemia in Children

    Kyowa Hakko Kirin Co. Ltd, (Kyowa Hakko Kirin), Kyowa Kirin International PLC (Kyowa Kirin International) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE: Ultragenyx) today announce that Crysvita (burosumab) has received a positive European Commission decision granting a conditional marketing authorisation to Kyowa Kirin for the treatment of X-linked hypophosphatemia (XLH) with radiographic evidence of bone disease in children 1 year of age and older and adolescents with growing skeletons. XLH is a rare, chronic progressive musculoskeletal disorder that affects children and adults.

  • Associated Press4 days ago

    Ultragenyx reports 4Q loss

    On a per-share basis, the Novato, California-based company said it had a loss of $1.89. Losses, adjusted for pretax gains, came to $2.27 per share. The results fell short of Wall Street expectations. The ...

  • Globe Newswire26 days ago

    Ultragenyx Appoints Camille L. Bedrosian, M.D. as Chief Medical Officer and Executive Vice President

    Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has appointed Camille L. Bedrosian, M.D. as Executive Vice President and Chief Medical Officer. In this role, Dr. Bedrosian will provide strategic leadership to the clinical development and translational research programs, and will oversee Medical Affairs, Global Clinical Development groups, Clinical Operations and Drug Safety/Pharmacovigilance.

  • Globe Newswirelast month

    Ultragenyx Announces Pricing of Public Offering of Common Stock

    Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the pricing of its underwritten public offering of 4,385,965 shares of its common stock at a price to the public of $57.00 per share, resulting in gross proceeds of $250 million before underwriting discounts. In addition, the company has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 657,895 shares of the company's common stock at the public offering price, less the underwriting discount. J.P. Morgan Securities LLC, BofA Merrill Lynch, Goldman Sachs & Co. LLC and Cowen are acting as joint book-running managers for the offering.

  • Business Wirelast month

    Anokion Announces Appointment of Dr. John Hohneker as Chief Executive Officer

    Anokion, a privately held biopharmaceutical company developing novel tolerance-inducing therapeutics for autoimmune diseases, today announced the appointment of John Hohneker, M.D., as president and chief executive officer, effective January 22. Dr. Hohneker joins Anokion from FORMA Therapeutics Inc., where he served as president of research and development. Prior to FORMA, he held roles of increasing responsibility at Novartis AG, most recently as senior vice president and global head of development for immunology and dermatology.

  • Ultragenyx Announces Interim Data from Early Stage Study
    Zacks2 months ago

    Ultragenyx Announces Interim Data from Early Stage Study

    Ultragenyx (RARE) announces data from phase I/II study on its AAV gene therapy candidate, DTX301, demonstrating normalization of ureagenesis in patients with ornithine transcarbamylase deficiency.

  • Business Wire2 months ago

    Newman Ferrara LLP Announces Corporate Governance Investigation of Ultragenyx Pharmaceutical Inc. - RARE

    Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Ultragenyx Pharmaceutical Inc. into potential breaches of fiduciary duty by the Company’s Board of Directors .

  • Globe Newswire2 months ago

    Ultragenyx Announces Positive Interim Topline Results From First Cohort of Phase 1/2 Clinical Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency 

    Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced positive interim safety and efficacy data from the first dose cohort of the Phase 1/2 study of DTX301, an adeno-associated virus (AAV) gene therapy for the treatment of ornithine transcarbamylase (OTC) deficiency. “We are encouraged by these initial data showing activity with our AAV8 vector in patients in the first, lowest-dose cohort. Patient 1 showed a normalization of ureagenesis that was maintained through 12 weeks, and we view this initial efficacy data as clinically meaningful and a promising indication of the potential of DTX301,” said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx.

  • Globe Newswire2 months ago

    Ultragenyx Announces Update to UX007 Development Program in Long-Chain Fatty Acid Oxidation Disorder Patients

    Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced an update to its development plan for UX007 in patients with long-chain fatty acid oxidation disorder (LC-FAOD). Following an end-of-phase 2 meeting with the FDA, the company is working to provide additional information to submit to FDA for consideration of an early filing based on the results from the Phase 2 study. The company is simultaneously completing the design of a Phase 3 study that could be used for registrational or confirmatory purposes.

  • Globe Newswire2 months ago

    Ultragenyx to Present at J.P. Morgan Healthcare Conference

    Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 at 10:30 am PT in San Francisco. The live and archived webcast of the company presentation will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. Ultragenyx is a biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.

  • MarketWatch2 months ago

    Ultragenyx sells rare drug voucher for $130 mln to Novartis

    Ultragenyx Pharmaceutical Inc. has agreed to sell a Food and Drug Administration-issued priority review voucher to Novartis AG for $130 million, the company said on Monday. Ultragenyx shares rose 3.4% ...

  • Does This Rare-Disease Biotech Have A Winner On Its Hands?
    Investor's Business Daily3 months ago

    Does This Rare-Disease Biotech Have A Winner On Its Hands?

    Ultragenyx popped to a seven-week high Monday on data from a Phase 3 trial for a drug to treat a rare bone disease.

  • MarketWatch3 months ago

    Ultragenyx shares rise 4% on late-stage results for rare disease therapy

    Ultragenyx Pharmaceutical Inc. shares rose 4.4% in premarket trade Monday after the company said that the rare disease therapy it is developing with Kyowa Hakko Kirin Co. Ltd. had positive results in a ...

  • Biotech Stock Roundup: RARE drug Gets FDA Nod, Acorda, Cytokinetics Hit by Pipeline Setbacks
    Zacks3 months ago

    Biotech Stock Roundup: RARE drug Gets FDA Nod, Acorda, Cytokinetics Hit by Pipeline Setbacks

    FDA approval for Ultragenyx's (RARE) rare disease drug and pipeline setbacks faced by Acorda and Cytokinetics were the main news this week in the biotech sector.

  • Ultragenyx's rhGUS Gets FDA Nod for Rare Genetic Disease
    Zacks3 months ago

    Ultragenyx's rhGUS Gets FDA Nod for Rare Genetic Disease

    Ultragenyx (RARE) clinches an FDA approval for rhGUS, a treatment option of mucopolysaccharidosis VII. The company assures the drug to be available in the United States by the month-end.

  • The Zacks Analyst Blog Highlights: Keryx Biopharmaceuticals, Bristol-Myers Squibb, Dynavax Technologies, Heron Therapeutics and Ultragenyx Pharmaceutical
    Zacks4 months ago

    The Zacks Analyst Blog Highlights: Keryx Biopharmaceuticals, Bristol-Myers Squibb, Dynavax Technologies, Heron Therapeutics and Ultragenyx Pharmaceutical

    The Zacks Analyst Blog Highlights: Keryx Biopharmaceuticals, Bristol-Myers Squibb, Dynavax Technologies, Heron Therapeutics and Ultragenyx Pharmaceutical

  • Associated Press4 months ago

    Ultragenyx reports 3Q loss

    The Novato, California-based company said it had a loss of $1.87 per share. The results matched Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research was also ...

  • 5 Biotech and Pharma Stocks with Key FDA Catalysts this November
    Zacks4 months ago

    5 Biotech and Pharma Stocks with Key FDA Catalysts this November

    Here is a look at five biotech and pharma stocks including Dynavax (DVAX) that have an important regulatory event lined up this month.

  • How Spark's Gene Therapy Win Could Also Be A Boon For These Biotechs
    Investor's Business Daily4 months ago

    How Spark's Gene Therapy Win Could Also Be A Boon For These Biotechs

    Spark's positive vote by an FDA committee could be a boon for other drugmakers working on gene therapies including Audentes, BioMarin and Ultragenyx.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes